A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma
收藏DataCite Commons2026-01-15 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005740/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma (NHL).
提供机构：
Vivli
创建时间：
2020-05-05
